A5023097678- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Breast Lesions and Carcinomas
- Advanced Breast Cancer Therapies
- Estrogen and related hormone effects
- Global Cancer Incidence and Screening
- Breast Implant and Reconstruction
- Monoclonal and Polyclonal Antibodies Research
- Cancer Cells and Metastasis
- Pharmacogenetics and Drug Metabolism
- Metastasis and carcinoma case studies
- Cancer and Skin Lesions
- Cancer Diagnosis and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- BRCA gene mutations in cancer
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Reconstructive Surgery and Microvascular Techniques
- Colorectal Cancer Treatments and Studies
- Cancer-related Molecular Pathways
- Inflammatory mediators and NSAID effects
- Economic and Financial Impacts of Cancer
- Cancer Risks and Factors
National Sagamihara Hospital
2016-2025
Kishokai Medical Corporation
2015-2024
The University of Tokyo
2023
The Cancer Institute Hospital
2019-2023
Nagasaki University
2023
Toranomon Hospital
2019-2023
National Cancer Center Hospital East
2019-2023
Hokkaido University of Science
2022
Baylor University Medical Center
2021
Texas Oncology
2021
Trastuzumab deruxtecan (T-DXd, formerly DS-8201a) is a novel human epidermal growth factor receptor 2 (HER2)-targeted antibody drug conjugate (ADC) with topoisomerase I inhibitor payload. A dose escalation and expansion phase study evaluated the safety activity of T-DXd in patients advanced HER2-expressing/mutated solid tumors. Here, results for at recommended doses (RDE) HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+/in situ hybridization-) breast cancer (ClinicalTrials.gov identifier:...
Objective: To update and examine national temporal trends in contralateral prophylactic mastectomy (CPM) determine whether survival differed for invasive breast cancer patients based on hormone receptor (HR) status age. Methods: We identified women diagnosed with unilateral stage I to III between 1998 2012 within the Surveillance, Epidemiology, End Results registry. compared characteristics undergoing breast-conserving surgery, mastectomy, CPM. then performed Cox proportional-hazards...
Human epidermal growth factor receptor 3 (HER3) is broadly expressed in breast cancer; high expression associated with an adverse prognosis. Patritumab deruxtecan (HER3-DXd) investigational HER3-targeted antibody-drug conjugate that being evaluated as a novel treatment HER3-expressing advanced cancer the U31402-A-J101 study.Adults disease progression on previous therapies were eligible. Patients dose-escalation, dose-finding, and dose-expansion parts received HER3-DXd 1.6-8.0 mg/kg...
IMPORTANCE While the prevalence of ductal carcinoma in situ (DCIS) breast has increased substantially following introduction breast-screening methods, clinical significance early detection and treatment for DCIS remains unclear.OBJECTIVE To investigate survival benefit surgery low-grade DCIS.
Radiotherapy (RT) after breast-conserving surgery (BCS) is a standard treatment option for the management of ductal carcinoma in situ (DCIS). We sought to determine survival benefit RT BCS on basis risk factors local recurrence.A retrospective longitudinal cohort study was performed identify patients with DCIS diagnosed between 1988 and 2007 treated by using SEER data. Patients were divided into following two groups: BCS+RT (RT group) alone (non-RT group). used patient prognostic scoring...
The gene encoding F-box protein FBXW7 is frequently mutated in many human cancers. Although most previous studies have focused on the tumor-suppressive capacity of tumor cells themselves, we determined that host microenvironment also suppresses cancer metastasis. Deletion Fbxw7 murine BM-derived stromal induced accumulation NOTCH and consequent transcriptional activation Ccl2. FBXW7-deficient mice exhibited increased serum levels chemokine CCL2, which resulted recruitment both monocytic...
2501 Background: DS-8201a is a HER2-targeted antibody drug conjugate with novel topoisomerase I inhibitor payload and linker technology. Methods: This ongoing phase 1 study (NCT02564900) enrolls subjects (sbj) HER2+ breast cancer (BC) post T-DM1, gastric (GC) trastuzumab, HER2 low BC (IHC 1+ or 2+, ISH-), other HER2-expressing solid tumors ≥1+). Results: [Results will be updated for presentation at meeting] From Sep 2015–Dec 2017, 212 sbj received ≥1 dose of DS-8201a; 200 5.4 6.4 mg/kg....
Ohi Y, Umekita Yoshioka T, Souda M, Rai Sagara Y & Tanimoto A(2011) Histopathology59, 776–780 Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer Aims: (ALDH1) has been identified as a reliable marker of stem cells, and its clinical significance prognostic indicator reported by several investigators. However, the ALDH1 (TN) cancer, high-risk lacking benefit specific therapy, remains to be solved. Methods results: We performed immunohistochemical...
Abstract Purpose We present the English version of The Japanese Breast Cancer Society (JBCS) Clinical Practice Guidelines for systemic treatment breast cancer, 2018 edition. Methods JBCS formed a task force to update Guidelines, 2015 edition, according Minds Handbook Guideline Development 2014. First, we set multiple outcomes each clinical question (CQ). Next, quantitative or qualitative systematic review was conducted outcomes, and strength recommendation CQ taken into consideration during...
526 Background: Patients (pts) with HER2+ metastatic breast cancer (mBC) are at high risk of developing brain metastases (BMs), and treatment options limited once BMs occur. T-DXd is an antibody-drug conjugate composed anti-HER2 antibody, a cleavable tetrapeptide-based linker, topoisomerase I inhibitor payload. On the basis findings phase 2 DESTINY-Breast01 trial (NCT03248492), was approved for adult pts unresectable or mBC who have received ≥2 prior anti-HER2–based regimens (US Europe) had...
Tumor-infiltrating lymphocytes (TILs) have potential value for stratifying the treatment of breast cancer (BC), though their precise use remains unclear. We aimed to investigate utility TILs using an alternative approach in different settings. reviewed patients with triple-negative (TN) or human epithelial growth factor receptor 2 (HER2)-positive invasive ductal carcinomas from a single institutional cohort and classified archived hematoxylin–eosin-stained samples terms TIL score as low (<10...
Aim Patients with cancer experience various forms of psychological distress, including depressive symptoms, which can impact quality life, elevate morbidity risk, and increase medical costs. Psychotherapy pharmacotherapy are effective for reducing symptoms among patients cancer, but most prefer psychotherapy. This study aimed to develop an efficient smartphone psychotherapy component address symptom. Methods was a decentralized, parallel‐group, multicenter, open, individually randomized,...
This prospective, multicenter, single-arm Phase II trial investigates the feasibility and safety of tailored axillary surgery (TAS) in patients with clinically node-positive breast cancer who are undergoing upfront surgery. The aims to establish criteria for safely omitting lymph node dissection (ALND) these cases, potentially shifting management by minimizing surgical complications preserving patients' quality life (QOL). study includes were diagnosed invasive cancer, particularly those...
Abstract This is an annual report by the Japanese Breast Cancer Society, which provides statistics on clinical data breast cancer in Japan, extracted from National Clinical Database-Breast Registry (NCD-BCR). includes update of 102,453 cases at 1339 institutions registered NCD-BCR 2022. Among 101,793 female patients, median age diagnosis was 62 years (interquartile range, 50–73 years), and 29.4% patients were premenopausal. Of these 15,437 (15.2%) 42,936 (42.2%) diagnosed with stage 0 I...
The number of breast cancer (BC) survivors has increased worldwide, but the landscape their non-cancer disease risks remains unclear, especially among Asian women. In JMDC claims database, which covers company employees and family members in Japan, women aged 18-74 years with without an incident BC were matched a 1:4 ratio for age entry timing to database between January 2005 December 2019. six cardiovascular diseases (myocardial infarction, heart failure, atrial fibrillation/flutter,...
Caveolin-1 and -2 (CAV1, CAV2) are closely linked genes localised to the fragile region of 7q31 (FRA7G), loss heterozygosity involving this has been reported in breast cancer. Several studies have suggested that CAV1 is a negative regulator HER2/neu signal transduction vitro. However, clinical significance cancer not yet clarified. We examined quantitatively mRNA levels CAV1, CAV2 162 cases using real-time PCR. protein expression was also by Western blotting immunohistochemistry. then...
Yoshioka T, Umekita Y, Ohi Souda M, Sagara Rai Y & Tanimoto A (2011) Histopathology 58 , 608–616 Aldehyde dehydrogenase 1 expression is a predictor of poor prognosis in node‐positive breast cancers: long‐term follow‐up study Aims: (ALDH1) has been identified as reliable marker cancer stem cells. The aim was to determine the prognostic significance ALDH1 study. Methods and results: Immunohistochemical analyses were performed on 257 invasive ductal carcinomas (IDCs), 109 matched lymph node...